SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets
CTG 7.260-0.4%Dec 2 4:30 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: richardred who wrote (3421)2/11/2014 1:27:22 PM
From: richardred  Read Replies (1) of 6521
 
RE-CPIX IMO FWIW Little CPIX also has a little kicker. Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States. The SA guy doesn't like this as much now RE:Hepatoren drug candidate
The Success Of Intercept Pharmaceuticals Is A Negative For Cumberland Pharmaceuticals.

No shot in the arm today, but with 3 1/2 in cash and total debt covered 10X current cash. Just maybe there's a chance for the early bird to get the worm.

Mallinckrodt acquires San Diego pharma firm Cadence for $1.3 billion



Cadence Pharmaceuticals makes Ofirmev, an injectable version of the drug acetaminophen, the active ingredient in Tylenol. (Rajesh Kumar Singh / Associated Press)

By Stuart Pfeifer

February 11, 2014, 9:02 a.m.

Ireland pharmaceutical company Mallinckrodt has agreed to acquire San Diego company Cadence Pharmaceuticals for about $1.3 billion in an effort to boost its specialty drugs portfolio.

Cadence, which commercializes drugs that are used in hospitals, is best known for Ofirmev, an injectable version of the drug acetaminophen, the active ingredient in Tylenol. Launched in January 2011, Ofirmev has been used to treat an estimated 6 million to 7 million patients.

Photos: Top 10 Southern California companies

“The acquisition of Cadence Pharmaceuticals is consistent with our goal of becoming a leading global specialty pharmaceuticals company,” said Mark Trudeau, chief executive of Mallinckrodt. "Ofirmev’s growth is driven by an expanding base of physicians who are prescribing the product for an increasing number of surgical patients, and we believe the product will be an outstanding addition to the brands component of Mallinckrodt’s specialty pharmaceutical segment.

"We have been impressed with the strong relationships that Cadence’s commercial organizations have established with customers in the hospital channel and are excited by the opportunity to build on these relationships to expand our platform in this area."

Cadence shares surged $2.91, or 26%, to $13.98 in morning trading.

“We are very proud of what our employees have accomplished, and in particular the very strong growth we have achieved with Ofirmev,” said Ted Schroeder, chief executive of Cadence Pharmaceuticals. “The relationships we’ve established with our customers and the benefits the drug has provided to millions of patients across the U.S. have contributed to the strong year-on-year growth we’ve seen for the product since launch.

"We believe Mallinckrodt is a natural fit to provide the resources and expertise that can expand patient access for Ofirmev. Additionally, this transaction will provide Cadence shareholders with a strong return on their investment.”

Mallinckrodt agreed to pay $14 per share for the company, a 27% premium to Cadence's Monday closing price of $11.07. The boards of both companies have approved the deal.

The acquisition, expected to close in March, will "significantly" boost Mallinckrodt's earnings per share, the company said in a news release.

Mallinckrodt shares were up $5.71, or 10%, at $65.02 Tuesday morning. The company reported net sales of $2.2 billion in its 2013 fiscal year, up from $2.1 billion the prior year. It has traded on the New York Stock Exchange since July, when it separated from former parent company Covidien.

latimes.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext